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Abstract
Background. Rotavirus is the leading cause of severe gastroenteritis in children !5 years of age and 
is responsible for 1500,000 deaths annually; 85% of this burden is in low-income countries 
eligible for financial support from the GAVI Alliance. We projected the uptake, health impact, and 
cost-effectiveness of introducing rotavirus vaccination in GAVI-eligible countries to help policy 
makers in prioritizing resources to gain the greatest health
improvements for their constituencies.
Methods. A demand forecast model was used to predict adoption of rotavirus vaccine in the 
poorest countries in the world. We then modeled health outcomes and direct costs of a 
hypothetical birth cohort in the target population for scenarios with and without a rotavirus 
vaccine with use of data on health outcomes of rotavirus infection, vaccine effectiveness, and 
immunization rates.
Results. Vaccination would prevent 2.4 million rotavirus deaths and 182 million disability-
adjusted life-years (DALYs) in 64 of the 72 GAVI-eligible countries introducing vaccine from 2007 
through 2025. The cost per DALY averted decreases over time, from a high of US$450 per DALY 
averted in the first year to a sustained low of $30 per DALY during 2017–2025, with a cumulative 
figure of $43 per DALY averted during 2008–2025. By applyingthe baseline scenario with an initial 
vaccine price of $7 per dose for a 2-dose vaccine, with a gradual decrease beginning in 2012 and 
stabilizing at $1.25 per dose by 2017, vaccination was very cost-effective in all GAVI-eligible 
countries with use of each country’s gross domestic product per DALY averted as a threshold.
Conclusions. Introduction of rotavirus vaccines into the world’s poorest countries is very cost-
effective and is projected to substantially reduce childhood mortality
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The developing world carries the greatest burden of
rotavirus infection, the leading cause of severe gastro-
enteritis in children !5 years of age. Of the 500,000
annual deaths caused by rotavirus, 190% occur in de-
veloping countries [1]. During the past 3 years, 2 new
rotavirus vaccines have been licensed and introduced
in the public sectors of several high- and middle-in-
come countries in the Americas and Europe. Although
the introduction of these vaccines in the developing
world could substantially reduce global rotavirus mor-
bidity and mortality, a 10–20 year delay [2] between
introduction of new vaccines in the industrialized world
and availability in the developing world is common [3,
4]. There has been a significant increase in support from
the global community to improve vaccine access and
to accelerate introduction of new vaccines in low-in-
come countries, including the formation of the GAVI
Alliance (formerly known as the Global Alliance for
Vaccines and Immunization), which supports vaccine
introduction programs in countries with a gross na-
tional income per capita of US$1000 or less. In 2006,
the same year during which rotavirus vaccine was first
introduced in affluent countries, it was also introduced
in the first GAVI-eligible country, Nicaragua, through
a donation program by the manufacturer. Sev-
eral additional low-income countries were poised to introduce
vaccine in 2008 with support from the GAVI Alliance.
Early introduction of new vaccines in low-income countries
is unprecedented, and it is important to understand the po-
tential health and economic impacts. The cost-effectiveness and
impact of rotavirus vaccination has been assessed for many
countries representing a wide range of income levels, vaccine
prices, and treatment costs [5–13]. However, no evaluations
have modeled the cost-effectiveness and impact of accelerated
introduction of rotavirus vaccines in high-burden countries
over time, nor have existing analyses investigated the dynamic
interplay between vaccine demand, impact, and cost-effective-
ness for a variety of pricing scenarios.
We conducted a global cost-effectiveness and impact analysis
of universal rotavirus vaccination programs for the world’s
poorest countries for the period 2007–2025. We estimated the
costs and benefits of introducing rotavirus vaccine in countries
eligible for GAVI Alliance support and estimated the projected
impact and cost-effectiveness for multiple vaccine price and
demand scenarios.
METHODS
We used a Microsoft Excel–based model to estimate the eco-
nomic and health burden of rotavirus and the cost-effectiveness
of vaccination in GAVI-eligible countries [14]. Principal model
inputs are described in Table 1. Countries were modeled in-
dividually, and results were grouped by World Health Orga-
nization (WHO) region (Table 2). The model estimated health
outcomes and health care costs associated with rotavirus for a
series of annual birth cohorts [40], each followed up for a 5-
year period. In addition, the model estimated the health care
costs averted and the reduction in disease burden after vaccine
introduction.
We conducted the analysis from a health care system per-
spective, focusing on direct medical costs from outpatient visits
and hospitalizations, including the cost of diagnostic tests, med-
ication, supplies, facilities, and personnel. Nonmedical costs to
households and productivity losses to caregivers are included
in the model, but results are not shown. Costs of informal
medical treatment are not included in the model. No economic
costs were included for cases that resulted in death or for pa-
tients who did not seek formal medical attention.
We estimated health burden in terms of disability-adjusted
life-years (DALYs), which quantify the years lost because of
mortality and the years lived with disability [41]. Estimates of
DALYs averted by universal rotavirus vaccination were used to
calculate the incremental cost-effectiveness ratio (ICER; US$
per DALY averted). Estimates are expressed in 2007 US dollars,
and all future costs and DALY estimates were discounted at a
rate of 3% annually.
Rotavirus-Associated Outpatient Visits, Hospitalizations, and
Mortality
We estimated rotavirus-associated outpatient visit and hospi-
talization rates based on the approach described by Parashar
et al [15]. We estimated rotavirus-associated outpatient visits
and hospitalizations by multiplying the total number of diar-
rhea-related outpatient visits and hospitalizations by the esti-
mated proportion attributable to rotavirus [15].
Estimates of rotavirus-associated mortality rates for each
country were taken from the WHO [1]. On the basis of existing
literature, rotavirus medical visits and deaths were distributed
into the following age categories: 0–2 months, 3–5 months, 6–
8 months, 9–11 months, 12–23 months, 24–35 months, 36–47
months, and 48–59 months [16, 17, 42–68].
We calculated DALYs attributable to rotavirus mortality
based on the standardized life expectancy at 1 year of age [69].
DALYs from cases of rotavirus disease resulting in outpatient
or hospital visits were calculated on the basis of default dis-
ability weights [36] and an estimated illness duration of 6 days
[70]. DALY estimates included age weights and an annual dis-
count rate of 3% [71].
Health Care Costs of Rotavirus
Direct medical costs include the cost of an outpatient visit or
hospital stay plus costs of diagnostic tests and medications.
Estimates of country-specific hospital costs were derived from
the WHO Choosing Interventions that are Cost Effective pro-
ject [72], which standardized costs for outpatient visits and per
diem hospitalizations according to geographical region and
mortality stratum. We calculated mean outpatient and hospital
unit costs for each region by taking a population-weighted
mean of country-specific cost estimates. We estimated the mean
length of hospital stay as 4 days [6, 16–35], and diagnostic and
medication costs were estimated as a proportion of the per visit
and per diem costs [73, 74]. Cost estimates were converted
from year 2000 international dollars to 2007 US dollars with
use of the Consumer Price Index [75], purchasing power parity,
and official exchange rates [76].
Vaccination Cost
Costs of vaccination include administration costs, price per
dose, and expected losses from waste. The cost of vaccine pro-
grams and administration was estimated using the WHO Global
Immunization Vision and Strategy costing tool [77]. Cost per
dose was calculated for each of the countries, and a regional,
weighted mean was calculated and used in the analysis. Because
of uncertainty of vaccine price over time, we calculated cost-
effectiveness with use of fixed prices of $1.25 per dose and $7
per dose and with use of price trajectories that project price
changes over time.
Table 2. Seventy-Two GAVI-Eligible Countries Categorized by
Analysis Group and World Health Organization Region
Countries where efficacy and safety of rotavirus vaccine among these or
similar populations have been confirmed in clinical trials at the time of the
analysis (projected adoption, 2008–2011)
Region of the Americas
Bolivia
Cuba
Guyana
Haitia
Honduras
Nicaragua
European Region
Armenia
Azerbaijan
Georgia
Kyrgyzstan
Moldova
Tajikistan
Ukraine
Uzbekistan
Countries likely to await results of ongoing rotavirus vaccine clinical trials
before introduction (projected adoption 2011–2018)
African region
Angolaa
Benin
Burkina Faso
Burundia
Cameroon
Central African
Republica
Chad
Comoros
Congoa
Congo DRa
Côte d’Ivoire
Eritrea
Ethiopia
The Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
São Tomé & Principe
Senegal
Sierra Leone
Tanzania
Togo
Uganda
Zambia
Zimbabwe
Eastern Mediterranean region
Afghanistana
Djibouti
Pakistan
Somalia
Table 2. (Continued.)
Sudan
Yemen
Southeast Asian region
Bangladesh
Bhutan
DPR Koreaa
India
Indonesia
Myanmar
Nepal
Sri Lanka
Timor-Leste
Western Pacific region
Cambodia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
a Countries not included in the current analysis because of projected adop-
tion dates after 2025.
Vaccine Effectiveness
We modeled the effectiveness of a live attenuated monovalent
human rotavirus vaccine administered orally with 2 doses of
diphtheria, tetanus, and pertussis (DTP) vaccine at ∼2 and ∼4
months of age, respectively. The effectiveness of vaccination
within a given birth cohort was estimated by combining in-
formation on vaccine efficacy, expected coverage of 1 and 2
doses, and the relative coverage of children at the highest risk
of mortality. Efficacy against severe rotavirus disease resulting
in hospitalizations or mortality was 85% [37]. Efficacy against
outpatient visits was estimated at 78% on the basis of the mean
efficacy against severe rotavirus gastroenteritis (85%) [37] and
any [38] rotavirus gastroenteritis (70%). One dose was assumed
to be 50% as efficacious as a full course.
Vaccine Coverage
We used coverage rates for the third dose of DTP from WHO
Immunization Coverage Estimates and Trajectories [77] to es-
timate coverage of rotavirus vaccine over time in each country.
We combined country-specific population coverage estimates
for the first and second doses of DTP with age-specific timing
estimated by region from 17 demographic and health surveys
from 2001 or later [78]. The model assumed a relative vaccine
coverage rate among children at the highest risk of rotavirus
mortality as 90% of the vaccination coverage of other children,
because it is possible that children who die of diarrhea may
have had less access to care, including routine vaccination.
Table 1. Variables Used in the Cost-Effectiveness and Impact Analyses
Variable Reference(s) Baseline estimate (range)
Distribution for
uncertainty analysis
Health
5-Year risk of hospitalization for rotavirus [15] 0.016 (0.012–0.020) Triangular
5-Year risk of outpatient visit for rotavirus [15] 0.202 (0.152–0.252) Triangular
Duration of hospital stay, days [6, 16–35] 4.0 (3.0–5.0) Triangular
YLL per death (discounted and weighted) [36] 34.0 NA
YLD per event (discounted and weighted) [36] 0.00037 NA
5-Year risk of mortality for rotavirus … Country-specific Triangular (25%)
Vaccine efficacy
Severe rotavirus gastroenteritis resulting in hospitalization or death [37] 0.85 (0.70–0.94) Log normal
Moderate rotavirus gastroenteritis resulting in outpatient visit [37, 38] 0.78 (0.58–0.89) Log normal
Effectiveness reduction with 1 dose Authors’ assumption 0.5 NA
Effectiveness reduction in subsequent seasons for mild cases [39] 0.04 NA
Health care cost, by region, 2007 US$ Triagular (25%)
Region of the Americas
Hospitalization … 122.41 …
Outpatient visit … 8.03 …
Vaccine program and administration … 0.64 …
European region
Hospitalization … 11.15 …
Outpatient visit … 7.20 …
Vaccine program and administration … 1.16 …
African region
Hospitalization … 47.39 …
Outpatient visit … 3.05 …
Vaccine program and administration … 0.53 …
Eastern Mediterranean region
Hospitalization … 73.06 …
Outpatient visit … 5.36 …
Vaccine program and administration … 0.69 …
Southeast Asian region
Hospitalization … 32.94 …
Outpatient visit … 1.72 …
Vaccine program and administration … 0.46 …
Western Pacific region
Hospitalization … 60.35 …
Outpatient visit … 3.39 …
Vaccine program and administration … 0.24 …
NOTE. NA, not applicable; YLD, years lived with disability; YLL, years of life lost.
Vaccination Demand Forecast and Vaccine Introduction
To estimate the total number of children vaccinated each year
from 2007 through 2025, we conducted a demand forecast
analysis for GAVI-eligible countries with use of Cennium Fore-
caster for Birth Cohort Vaccines in Developing Countries (Ap-
plied Strategies Consulting), a decision-support software.
Model inputs. Model inputs included country-level pop-
ulation and birth cohort data, vaccine coverage rates, funding
options, vaccine dosing schedule, vaccine price, and expected
year of introduction [2]. The demand forecast model incor-
porated population and birth cohort estimates for each country
through 2025, to capture demographic trends [69].
Price-demand scenarios. Three price-demand scenarios
were developed for the analysis: baseline, accelerated, and de-
layed. Changes in the mean price of a single dose of a 2-dose
vaccine for each scenario are shown in Figure 1. For all 3 price-
demand scenarios, an initial price of US$7 per dose for a 2-
dose vaccine was assumed on the basis of existing multinational
supplier prices for lower-middle–income countries in Latin
America [79] and an eventual price stabilization at $1.25 per
dose after developing country manufacturers enter the market
and increase supply with lower-cost products. This long-run
price was estimated on the basis of a cost-of-goods analysis
conducted in 2005 and assumes that most supply would be
produced by manufacturers in developing countries, either with
their own products or with transferred technology from mul-
tinational suppliers by 2017.
For the baseline price-demand scenario, vaccine price begins
Figure 1. Annual price per dose for a 2-dose rotavirus vaccine and the number of children vaccinated for 3 price-demand scenarios.
to decrease in 2012, when new market entrants are expected,
with price stabilizing at $1.25 per dose by 2017. In the accel-
erated price-demand scenario, vaccine price decreases sooner
(2010) to reflect potentially earlier entry of additional products
and stabilizes at $1.25 per dose by 2016. For the delayed price-
demand scenario, price first decreases in 2014 and does not
stabilize at $1.25 per dose until 2020. The delayed scenario
represents potential delays in new market entrants because of
uncertainty of product development success and timelines. We
projected that the last countries to adopt universal rotavirus
vaccination will reach vaccine coverage targets in 2021 and will
realize the full benefits of vaccination by 2025.
Country adoption schedules. Demand estimates require
predictions about which countries will adopt vaccine and about
the timing of their adoption. Early adopters, projected to in-
troduce vaccine during 2008–2011, included countries in Latin
America and Eastern Europe where vaccine efficacy and safety
have been confirmed in clinical trials for these or similar pop-
ulations. Countries in Africa and Asia likely to await results of
ongoing clinical trials before vaccine introduction are projected
to adopt from 2011 through 2018. For purposes of the analysis,
we accounted for the likely scenario that some countries will
not adopt before 2025 for reasons of political instability and/
or very poor vaccine adoption history. Although we cannot
predict with certainty which countries these will be, we have
excluded 8 countries, representing 10% of the GAVI-eligible
birth cohort. Countries are presented by adoption timing and
WHO region in Table 2.
We used a criteria-based prediction process to estimate the
year of vaccine introduction within the 2 major adoption pe-
riods. Countries that have (1) relatively high coverage rates of
the third dose of DTP (80%), (2) introduced hepatitis B and/
or Haemophilus influenzae type b vaccine, (3) a significant bur-
den of rotavirus disease, and (4) expressed an interest in adopt-
ing rotavirus vaccine were predicted to adopt early. Countries
that met most but not all of these criteria were next in the
adoption schedule. This criteria-based prediction process con-
tinued until all countries were included. On the basis of the
introduction patterns of hepatitis B vaccine, we assumed that
countries would need 2–4 years after vaccine introduction to
reach maximum expected coverage levels.
Summary Outcomes
The 2 primary outcome measures were the number of deaths
averted (total and per 1000 children vaccinated) and incre-
mental cost-effectiveness. The ICER is the net cost of vacci-
nation from the health care system perspective divided by the
change in DALYs attributable to rotavirus, compared with cur-
rent vaccination practice. The ICER was calculated for each
year, country, region, and demand scenario.
Sensitivity and Uncertainty Analyses
One-way sensitivity analyses were conducted to assess the im-
pact of specific variables on the number of deaths averted and
cost-effectiveness of vaccination for the baseline price-demand
scenario. Variables included rotavirus mortality incidence, vac-
cine efficacy against hospitalization and mortality, relative cov-
erage (ability to reach children at highest risk of death), vac-
cination systems costs, and timing of vaccine dosing. The 2
alternative price-demand scenarios (accelerated and delayed)
were also included in the sensitivity analysis.
Table 3. Projected Impact and Cost-Effectiveness of Rotavirus Vaccination by Region and Total for GAVI-Eligible Countries during
the Period 2007–2025
Variable
WHO region
AMR EUR AFR EMR SEAR WPR All GAVI Alliance regions
Regional GDP per capita (population-
weighted),a mean US$ 1900 2100 670 880 1020 800 970
Total impact
Total no. of deaths averted 16,322 53,174 1,025,084 188,859 1,113,609 57,479 2,431,922
Total DALYs averted 577,411 1,813,693 34,915,277 6,437,204 37,957,729 1,961,122 82,872,424
Impact per 1000 children vaccinated
No. of deaths averted (10%–90%
uncertainty) 1.3 (0.8–1.5) 2.3 (1.3–2.5) 5.3 (3.3–5.7) 3.0 (1.6–3.1) 3.0 (1.7–3.2) 2.0 (1.0–2.0) 3.6 (2.1–3.7)
DALYs averted 45 80 180 100 102 67 123
Health care visits averted 141 147 132 133 139 139 137
Medical costs averted, 2007 US$ 2533 1653 913 1480 617 1152 857
Cost-effectiveness
Cost/DALY averted ($7.00 per
dose), 2007 US$ 289 201 78 419 147 210 118
Cost/DALY averted ($1.25 per
dose), 2007 US$ 26 42 14 66 28 29 21
Cumulative cost/DALY averted
(2007–2025), 2007 US$
(10%–90% uncertainty) 118 (111–232) 105 (97–195) 22 (17–31) 33 (25–54) 54 (50–99) 81 (76–151) 43 (39–71)
NOTE. AFR, African region; AMR, region of the Americas; DALY, disability-adjusted life-year; EMR, eastern Mediterranean region; EUR, European region;
GDP, gross domestic product; SEAR, Southeast Asian region; WHO, World Health Organization; WPR, western Pacific region.
a Data are from [69, 80].
A probabilistic uncertainty analysis was done to assess the
combined effect of multiple uncertain variables on vaccination
impact (deaths averted) and cost-effectiveness (US$ per DALY
averted). Monte Carlo simulation was performed using distri-
butions for the key input variables, including rotavirus mor-
tality, vaccine efficacy, vaccination systems costs, and relative
coverage. Multiple iterations (10,000) randomly drew values
from the input variable distributions and generated a distri-
bution of output values and corresponding uncertainty limits
(tenth and 90th percentiles of the output distributions).
RESULTS
Demand forecast and uptake. The expected trajectory of
price decrease and uptake for the 3 price-demand scenarios are
shown in Figure 1. For all scenarios, vaccination is expected to
reach almost 62 million children in 2025.
Vaccine impact. Projected impact and cost-effectiveness es-
timates for the 64 countries included in this analysis are pre-
sented by region in Table 3. From 2007 through 2025, by using
the baseline scenario, universal vaccination would result in 2.4
million fewer deaths due to rotavirus and in 182 million fewer
DALYs, primarily in the Southeast Asian and African regions.
Vaccination would result in 137 medical visits averted and $857
in medical expenses averted for every 1000 children vaccinated.
For every 1000 children vaccinated, the medical costs averted
are highest in Latin America ($2533) and lowest in sub-Saharan
Africa ($913) and Southeast Asia ($617). Conversely, the health
benefits are greatest in Africa (180 DALYs averted) and South-
east Asia (102 DALYs averted) and lowest in Latin America (45
DALYs averted).
Figure 2 shows the estimated annual numbers of deaths
averted and deaths averted per 1000 children vaccinated over
time for each of the 3 price-demand scenarios. For the baseline
scenario, the annual number of deaths averted climbs from
10,000 in 2008 to ∼150,000 by 2014, reaching a sustained level
of 225,000 annual deaths averted by 2021. The number of
deaths averted per 1000 children vaccinated increases from 1.0
in 2008 to ∼3.0 in 2011 and ∼3.5 after 2018. For the baseline
scenario, the number of annual deaths averted climbs rapidly
between 2010 and 2020. The annual numbers of deaths averted
and deaths averted per 1000 children vaccinated are similar for
the baseline and accelerated scenarios. In the delayed scenario,
the initial increase in the number of annual deaths averted
occurs in 2013 and approaches a maximum only after 2023.
The delayed uptake would result in 543,720 fewer deaths
averted, compared with the baseline price-demand scenario.
Cost-effectiveness. For the baseline scenario, the cost-ef-
fectiveness ratio of rotavirus vaccination in GAVI-eligible coun-
tries would be $43 per DALY averted for the entire period
during 2007–2025 (Table 3). The ICER ranges from $22 per
DALY averted in Africa to $118 per DALY averted in Latin
America. The World Health Report (2002) suggests that “very
cost-effective interventions” are those that “avert each addi-
tional DALY at a cost less than GDP [gross domestic product]
Figure 2. No. of deaths averted per 1000 children vaccinated and total no. of deaths averted annually for the 3 following price-demand scenarios:
(1) base-case demand, (2) delayed demand, and (3) accelerated demand.
per capita” [81, p 108] and that interventions with a cost-
effectiveness ratio ($/DALY averted) of 1–3 times the gross
domestic product per capita are cost-effective. By this standard,
rotavirus vaccination would be very cost-effective in all the
regions considered over the period. If vaccine prices do not
decrease as projected, vaccination would meet only the standard
of cost-effectiveness in some countries.
With use of a constant price of $7 per dose for a 2-dose
vaccine, the ICER ranges from $78 to $419 per DALY averted.
At the projected market mature price of $1.25, the ICER ranges
from $14 per DALY averted in sub-Saharan Africa to $66 per
DALY averted in the eastern Mediterranean region. At that
price, rotavirus vaccines represent a very cost-effective inter-
vention for GAVI-eligible countries in all regions.
Figure 3 shows the estimated cost-effectiveness of vaccination
over time, including the annual ICER for each year for the 3
price-demand scenarios and the cumulative ICER for the base-
line scenario. For all 3 price-demand scenarios, the annual ICER
decreases from 1$400 per DALY averted to ∼$25 per DALY
averted. The cumulative ICER for the baseline scenario de-
creases over time, reaching $43 per DALY averted.
Sensitivity analysis. Changes in assumptions for key var-
iables resulted in minimal changes in the cost-effectiveness of
universal rotavirus vaccination (Figure 4). The cost-effective-
ness of the vaccine decreases to a low of $33 per DALY averted
based on the accelerated scenario and increases to $73 per DALY
averted if vaccine efficacy is only 50%. Even at the highest cost-
effectiveness ratio of $73 per DALY averted, the rotavirus vac-
cine remains a very cost-effective intervention in GAVI-eligible
countries for the projected period during 2007–2025. The num-
ber of deaths averted ranged from 1.4 million with a vaccine
efficacy of 50% to an upper range of 3 million when baseline
rotavirus mortality rates are increased by 25%. Upper and lower
uncertainty limits from the probabilistic analysis are also pre-
sented by region for deaths averted per 1000 children vaccinated
and cost-effectiveness in Table 3.
DISCUSSION
Introduction of rotavirus vaccines in GAVI-eligible countries
will be cost-effective and could avert the deaths of 2.5 million
children from 2007 through 2025, with annual reductions in
mortality of up to 225,000 children. Our findings suggest that
cost-effectiveness ratios decrease over time and that the impact
of vaccination on overall mortality and mortality rates in-
creases. These temporally related outcomes are influenced by
similar factors—primarily, decreases in vaccine price over time
and vaccine uptake by countries with a higher burden of ro-
tavirus later during the introduction period. Early-adopter
countries in Latin American and European regions are bur-
dened by significant morbidity and associated hospital costs
related to rotavirus, compared with countries in the African
and Asian regions; however, their underlying mortality rates
are lower. In addition, the initial vaccine price is anticipated
to be higher than in subsequent years. Once countries with a
higher burden of rotavirus in Africa and Asia introduce the
vaccine, the price is likely to decrease as production in devel-
oping countries increases, both global and region-specific cost-
effectiveness ratios will improve, and impact will increase
substantially.
Figure 3. Annual incremental cost-effectiveness ratio (ICER) for 3 price-demand scenarios and cumulative cost-effectiveness ratio for baseline
scenario. The annual ICER is calculated for each year. The cumulative ICER is for the period up to that year. DALY, disability-adjusted life-year.
Figure 4. One-way sensitivity analysis of key variables for the cumulative cost per disability-adjusted life-years (DALYs) averted and number of
deaths averted during the period 2007–2025. ICER, incremental cost-effectiveness ratio.
Our sensitivity analysis assessed the impact of variability in
rotavirus mortality, vaccine efficacy, relative coverage, timing
of administration of vaccine doses, vaccine system costs, and
our price-demand scenarios on health outcomes and cost-ef-
fectiveness of universal rotavirus vaccination. For all adjust-
ments, rotavirus vaccination remained cost-effective or very
cost-effective. Although our sensitivity analysis accounted for
changes in vaccination coverage, our model required holding
infant and child mortality rates from 2004 constant. Possible
secular reductions in diarrhea- and rotavirus-associated mor-
tality because of factors such as economic development or im-
provements in access to care could result in an overestimate
of both the cost-effectiveness and the total impact of universal
vaccination. Societal costs and costs associated with the infor-
mal health care sector also are not included in this analysis.
Although these costs have been shown to have a nominal im-
pact on the incremental cost-effectiveness of vaccination pro-
grams, our cost-effectiveness results would be more favorable
if we had captured the full extent of medical costs averted
through rotavirus vaccination. In addition, although the 3-dose
vaccine schedule was not modeled, the conclusions of this anal-
ysis would not be expected to differ between the 2- and 3-dose
regimens.
Projections are based on several assumptions that could sub-
stantially affect the cost-effectiveness and impact of rotavirus
vaccination over time. First, our 3 price-demand scenarios as-
sume that results of clinical trials in Africa and Asia will be
favorable enough for adoption. Should results not provide com-
pelling evidence for rotavirus vaccine introduction, demand in
these regions is likely to be very limited. Second, the scenarios
depend on the entry of manufacturers in developing countries
in the rotavirus vaccine market. Development efforts by emerg-
ing suppliers are underway, but uncertainty regarding the tim-
ing and extent of market entry remains and is also dependent
on vaccine demand. Finally, although we have used historical
trends to predict when countries are likely to introduce rota-
virus vaccination, it is difficult to reliably predict adoption
patterns. Despite these limitations, our current price-demand
scenarios are based on the most reliable data currently available
and are broad enough to capture potential delays in both de-
mand and introduction.
For all vaccine prices and price-demand scenarios included
in our analysis, universal rotavirus vaccination is very cost-
effective or cost-effective in all GAVI-eligible countries and can
save the lives of millions of children. However, a program can
provide good value for money but remain unaffordable and,
thus, unable to achieve and sustain desired results. Initial vac-
cine prices, although substantially discounted by multinational
pharmaceutical companies, are still out of reach for many de-
veloping countries, making the subsidies provided by the GAVI
Alliance and other potential donors essential for accelerated
vaccine introduction. We showed the impact of a modest delay
in price decrease and uptake in our delayed scenario, in which
the opportunity to save the lives of 1540,000 children is missed.
Although universal rotavirus vaccination programs would be
cost-effective even at the highest vaccine price included in our
analysis, subsidies must be sustained or the price of the vaccine
must decrease to ensure introduction in low-income, high-
burden countries.
In addition to vaccine affordability, decision makers will be
influenced by factors such as health system capacity and the
costs associated with expanding existing immunization services
to accommodate new vaccines. Policy makers must weigh the
political, social, and economic considerations of allocating pre-
cious resources in the face of many important and often com-
peting health care and development priorities. Because more
countries will consider adoption of rotavirus vaccination in the
coming years, this analysis was designed to complement existing
and forthcoming clinical and epidemiological data to provide
the evidence base necessary to make well-informed policy and
funding decisions. Our findings indicate that rotavirus vacci-
nation is cost-effective and has the potential to save hundreds
of thousands of young children each year in developing
countries.
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13. Lorgelly PK, Joshi D, Iturriza Gómara M, Gray J, Mugford M. Exploring
the cost effectiveness of an immunization programme for rotavirus
gastroenteritis in the United Kingdom. Epidemiol Infect 2008; 136:
44–55.
14. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Potential
cost-effectiveness of vaccination for rotavirus gastroenteritis in eight
Latin American and Caribbean countries. Rev Pan Am Salud Publica
2007; 21:205–16.
15. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global
illness and deaths caused by rotavirus disease in children. Emerg Infect
Dis 2003; 9:565–72.
16. Mrukowicz JZ, Krobicka B, Duplaga M, et al. Epidemiology and impact
of rotavirus diarrhoea in Poland. Acta Paediatr Suppl 1999; 88:53–60.
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29. Gómez JA, Nates S, De Castagnaro NR, Espul C, Borsa A, Glass RI.
Anticipating rotavirus vaccines: review of epidemiologic studies of ro-
tavirus diarrhea in Argentina. Rev Panam Salud Publica 1998; 3:69–78.
30. Effler PV, Holman RC, Parashar UD, Glass RI. Diarrhea-associated
hospitalizations among children in Hawaii. Hawaii Med J 2000; 59:
362–5.
31. Ford-Jones EL, Wang E, Petric M, Corey P, Moineddin R, Fearon M.
Hospitalization for community-acquired, rotavirus-associated diarrhea:
a prospective, longitudinal, population-based study during the seasonal
outbreak. The Greater Toronto Area/Peel Region PRESI Study Group.
Pediatric Rotavirus Epidemiology Study for Immunization. Arch Pe-
diatr Adolesc Med 2000; 154:578–85.
32. Parashar UD, Holman RC, Clarke MJ, Bresee JS, Glass RI. Hospital-
izations associated with rotavirus diarrhea in the United States, 1993
through 1995: surveillance based on the new ICD-9-CM rotavirus-
specific diagnostic code. J Infect Dis 1998; 177:13–7.
33. Parashar UD, Holman RC, Bresee JS, et al. Epidemiology of diarrheal
disease among children enrolled in four West Coast health maintenance
organizations. Vaccine Safety Datalink Team. Pediatr Infect Dis J
1998; 17:605–11.
34. Buigues RP, Duval B, Rochette L, et al. Hospitalizations for diarrhea
in Quebec children from 1985 to 1998: estimates of rotavirus-associated
diarrhea. Can J Infect Dis 2002; 13:239–44.
35. Berner R, Schumacher RF, Hameister S, Forster J. Occurrence and
impact of community-acquired and nosocomial rotavirus infections—
a hospital-based study over 10 y. Acta Paediatr 1999; 88:48–52.
36. Murray CJL, Lopez AD. The global burden of disease: a comprehensive
assessment of mortality and disability from diseases, injuries and risk
factors in 1990 and projected to 2020. Vol. 1. Cambridge: Harvard
University Press, 1996.
37. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al.; Human Ro-
tavirus Vaccine Study Group. Safety and efficacy of an attenuated vac-
cine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:
11–22.
38. De Vos B, Vesikari T, Linhares AC, et al. A rotavirus vaccine for pro-
phylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis
J 2004; 23(Suppl):S179–82.
39. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live
attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect
Dis J 2004; 23:937–43.
40. United Nations Children’s Fund. The state of the world’s children 2004.
2002. Available at: http://www.unicef.org/sowc04/index.html. Accessed
24 May 2004.
41. Murray C, Lopez A. The global burden of disease: a comprehensive
assessment of mortality and disability from diseases, injuries, and risk
factors in 1990 and projected to 2020. In: Global burden of disease
and injury series. Vol. 1, xxxii. Boston: School of Public Health, Har-
vard University, 1996:990.
42. Villa S, Guiscafre H, Martinez H, Munoz O, Gutierrez G. Seasonal
diarrhoeal mortality among Mexican children. Bull WHO 1999; 77:
375–80.
43. Gomez JA, Sordo ME, Gentile A. Epidemiologic patterns of diarrheal
disease in Argentina: estimation of rotavirus disease burden. Pediatr
Infect Dis J 2002; 21:843–50.
44. Velazquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a
marker of protection against natural rotavirus infection and disease. J
Infect Dis 2000; 182:1602–9.
45. Gonzalez FS, Sordo ME, Rowensztein G, et al. Rotavirus diarrhea:
impact in a pediatric hospital of Buenos Aires. Medicina 1999; 59:
321–6.
46. Cardoso DD, Soares CM, Dias e Souza MB, et al. Epidemiological
features of rotavirus infection in Goiania, Goias, Brazil, from 1986 to
2000. Memorias do Instituto Oswaldo Cruz 2003; 98:25–9.
47. Bok K, Castagnaro NC, Diaz NE, et al. Rotavirus laboratory network:
results after one year of observation [in Spanish]. Rev Arg Microbiol
1999; 31:1–12.
48. Bok K, Castagnaro N, Borsa A, et al. Surveillance for rotavirus in
Argentina. J Med Virol 2001; 65:190–8.
49. Barraza P, Avendano LF, Spencer E, Calderon A, Prenzel I, Duarte E.
Hospital infection caused by rotaviruses in infants, Santiago, Chile.
Boletin de la Oficina Sanitaria Panamericana 1986; 101:328–38.
50. Urrestarazu MI, Liprandi F, De Suarez EP, Gonzalez R, Perez-Schael
I. Etiological, clinical, and sociodemographic characteristics of acute
diarrhea in Venezuela [in Spanish]. Rev Panam Salud Publica 1999;
6:149–56.
51. Perez-Schael I, Gonzalez R, Fernandez R, et al. Epidemiological features
of rotavirus infection in Caracas, Venezuela: implications for rotavirus
immunization programs. J Med Virol 1999; 59:520–6.
52. Hsu VP, Abdul Rahman HB, Wong SL, et al. Estimates of the rotavirus
disease burden in Malaysia. J Infect Dis 2005; 19(Suppl 1):S80–6.
53. Nelson EA, Tam JS, Bresee JS, et al. Estimates of rotavirus disease
burden in Hong Kong: hospital-based surveillance. J Infect Dis
2005; 192(Suppl 1):S71–9.
54. Chen KT, Chen PY, Tang RB, et al. Sentinel hospital surveillance for
rotavirus diarrhea in Taiwan, 2001–2003. J Infect Dis 2005; 192(Suppl
1):S44–8.
55. Jiraphongsa C, Bresee JS, Pongsuwanna Y, et al.; Rotavirus Surveillance
Project Thailand Study Group. Epidemiology and burden of rotavirus
diarrhea in Thailand: results of the sentinel surveillance. J Infect Dis
2005; 192(Suppl 1):S87–93.
56. Cama RI, Parashar UD, Taylor DN, et al. Enteropathogens and other
factors associated with severe disease in children with acute watery
diarrhea in Lima, Peru. J Infect Dis 1999; 179:1139–44.
57. Cunliffe NA, Gondwe JS, Kirkwood CD, et al. Effect of concomitant
HIV infection on presentation and outcome of rotavirus gastroenteritis
in Malawian children. Lancet 2001; 358:550–5.
58. Mpabalwani M, Oshitani H, Kasolo F, et al. Rotavirus gastro-enteritis
in hospitalized children with acute diarrhoea in Zambia. Ann Trop
Paediatr 1995; 15:39–43.
59. Fang ZY, Wang B, Kilgore PE, et al. Sentinel hospital surveillance for
rotavirus diarrhea in the People’s Republic of China, August 2001–July
2003. J Infect Dis 2005; 192(Suppl 1)S94–9.
60. Bahl R, Ray P, Subodh S, et al. Incidence of severe rotavirus diarrhea
in Delhi and the G and P types of the infecting strains. J Infect Dis
2005; 192(Suppl 1):S114–9.
61. De Francisco A, Hall A, Schellenberg JR, Greenwood AM, Greenwood
BM. The pattern of infant and childhood mortality in Upper River
Division, the Gambia. Ann Trop Paediatr 1993; 13:345–52.
62. Jaffar S, Leach A, Greenwood AM, et al. Changes in the pattern of
infant and childhood mortality in upper river division, the Gambia,
from 1989 to 1993. Trop Med Int Health 1997; 2:28–37.
63. Shamebo D, Muhe L, Sandstrom A, Freij L, Krantz I, Wall S. The
Butajira Rural Health Project in Ethiopia: a nested case-referent (con-
trol) study of under-5 mortality and its health and behavioural deter-
minants. Ann Trop Paediatr 1994; 14:201–9.
64. Khalique N, Sinha SN, Yunus M, Malik A. Early childhood mortality—
a rural study. J R Soc Health 1993; 113:247–9.
65. Hirve S, Ganatra B. A prospective cohort study on the survival ex-
perience of under five children in rural western India. Indian Pediatr
1997; 34:995–1001.
66. van Tran D, van Thuan C, Tuan T, Dung PH, Persson L, Grabe M.
Survey on immunization, diarrhoeal disease and mortality in Quang
Ninh Province, Vietnam. J Trop Pediatr 1991; 37:280–5.
67. Jinadu MK, Olusi SO, Agun JI, Fabiyi AK. Childhood diarrhoea in
rural Nigeria. I. Studies on prevalence, mortality and socio-environ-
mental factors. J Diarrhoeal Dis Res 1991; 9:323–7.
68. Baqui AH, Sabir AA, Begum N, Arifeen SE, Mitra SN, Black RE. Causes
of childhood deaths in Bangladesh: an update. Acta Paediatrica 2001;90:
682–90.
69. Population Division of the Department of Economic and Social Affairs
of the United Nations Secretariat. World population prospects: the 2006
revision. Available at: http://esa.un.org/unpp/. Accessed August 2007.
70. Liddle JL, Burgess MA, Gilbert GL, et al. Rotavirus gastroenteritis:
impact on young children, their families and the health care system.
Med J Aust 1997; 167:304–7.
71. Baltussen R, Adam T, Tan Torres T, et al. Generalized cost effectiveness
analysis: a guide. Geneva: World Health Organization: 2002.
72. World Health Organization. Prices for hospital and health centres.
2008. Available at: http://www.who.int/whosis/en/. Accessed 21 Feb-
ruary 2008.
73. World Health Organization. Review of treatment cost protocol studies.
Geneva: WHO Department of Vaccines and Biologicals, 2001:1–32.
74. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Economic
and health burden of rotavirus gastroenteritis for the 2003 birth cohort
in eight Latin American and Caribbean countries. Rev Panam Salud
Publica 2007; 21:192–204.
75. Bureau of Labor Statistics. Consumer price index. 2000–2002. Available
at: http://www.bls.gov/cpi/cpi_dr.htm. Accessed 10 April 2008.
76. World Development Indicators Online. 2004. Available at: http://www
.worldbank.org/data/wdi2004/. 3 May 2004.
77. Wolfson LJ. WHO Immunization Coverage Estimates and Trajectories
(WHO ICE-T). Geneva: World Health Organization, Department of
Immunization, Vaccines, and Biologicals, 2008:5.
78. DHS. Demographic and Health Surveys. 2001–2007, Measures DHS.
Available at: http://www.measuredhs.com. Accessed 21 February 2008.
79. Pan American Health Organization. 2008 PAHO revolving fund vaccine
prices. Immunization Newsletter 2008; 1:1.
80. IMF. World economic outlook database. 2008. Available at: http://
www.imf.org/external/pubs/ft/weo/2008/01/. Accessed 21 April 2008.
81. World Health Organization. Some strategies to reduce risk, in World
Health Report 2002: reducing risk, promoting healthy lives. Geneva:
World Health Organization, 2002:100–44.
